Federal

Robert Bradway, chief executive of Thousand Oaks pharma giant Amgen Inc., has grown increasingly frustrated at the government’s unwillingness to come to terms with Amgen over its $27.8 billion acquisition deal of Irish pharma company Horizon Therapeutics. That deal, announced last December, hit a major stumbling block in May when the Federal Trade Commission filed […]